EUVIMEDEUVIMED entdecken
Crossref

Comparison of perennial and preseasonal allergoid immunotherapy in grass pollen allergic patients

Zeynep Celebi Sözener, Dilşad Mungan, Ömür Aydin, Derya Seçil, Münevver Nur Pinar, Yavuz Selim Demirel, Betul Ay E Sin

Asian Pacific Journal of Allergy and Immunology · 2023

DOI: 10.12932/ap-280121-1048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2023. Verfasst von Zeynep Celebi Sözener und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ankara University School of Medicine Department of Chest diseases Division of Immunology and Allergy, Ankara, Turkey. Hauptthemen laut MEDLINE: Interleukin-10, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The clinical and immunological efficacy of preseasonal allergoid immunotherapy has been previously investigated, however, studies comparing the effectiveness of the two protocols are limited in the literature. OBJECTIVE: The aim of this study is to compare the clinical and immunological efficacy of pre-seasonal and perennial allergoid immunotherapy. METHODS: This is a prospective cross sectional two-arm study. During the season; symptom and medication scores were filled. Before and at the end of the season; RQLQ was applied, Phl p sIgE, sIgG4 and IL-10 levels were measured. RESULTS: In preseasonal group patients had better symptom control for most of the weeks, particularly during the peak pollen period (April: w-2 & w-4, p = 0.04; May: w-2, p = 0.02; June: w-1, w-2, p = 0.02; w-3, w-5, p = 0.03; July: w-2, p = 0.01; w-3, p = 0.02; w-4, p = 0.04). In the perennial group, sIgG4 [1st time point: preseasonal 0.02 mgA/L vs perennial 0.13 mgA/L (p < 0.0001); 2nd time point: preseasonal 0.52 mgA/L vs perennial 0.33 mgA/L; 3rd time point: preseasonal 0.04 mgA/L vs perennial 0.12 mgA/L (p < 0.0001)] and IL-10 (1st time point: preseasonal 1.45 pg/ml vs perennial 2.03 pg/ml; 2nd time point: preseasonal 2.29 pg/ml vs perennial 2.19 pg/ml; 3rd time point: preseasonal 2.32 pg/ml vs perennial 2.16 pg/ml) levels were higher and more stable. CONCLUSIONS: Preseasonal immunotherapy provided better control of symptoms throughout the pollen season. However, the blocking antibody response was stronger and more permanent in the perennial immunotherapy group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-10ImmunotherapyHumansAllergoidsCross-Sectional StudiesProspective StudiesPollenPoaceae

Substanzen

AllergoidsInterleukin-10

Autor:innen und Institutionen

  • Ankara University School of Medicine Department of Chest diseases Division of Immunology and Allergy, Ankara, Turkey.
  • Ankara University Faculty of Science, Department of Biology, Ankara, Turkey.

Zitieren

APA

Sözener, Z. C., Mungan, D., Aydin, Ö., Seçil, D., Pinar, M. N., Demirel, Y. S., & Sin, B. A. E. (2023). Comparison of perennial and preseasonal allergoid immunotherapy in grass pollen allergic patients. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-280121-1048

Vancouver

Sözener ZC, Mungan D, Aydin Ö, Seçil D, Pinar MN, Demirel YS, et al. Comparison of perennial and preseasonal allergoid immunotherapy in grass pollen allergic patients. Asian Pacific Journal of Allergy and Immunology. 2023. doi:10.12932/ap-280121-1048

BibTeX
@article{Szener2023,
  author = {Sözener, Zeynep Celebi and Mungan, Dilşad and Aydin, Ömür and Seçil, Derya and Pinar, Münevver Nur and Demirel, Yavuz Selim and Sin, Betul Ay E},
  title = {Comparison of perennial and preseasonal allergoid immunotherapy in grass pollen allergic patients},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2023},
  doi = {10.12932/ap-280121-1048}
}
Kostenlos starten →